ClinicalTrials.gg

Akeso clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 166 studies whose lead sponsor is Akeso or one of 1 company grouped under it. 67 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Akeso with Bristol-Myers Squibb and AstraZeneca →

Pipeline: 17 programs

Each counted once: 17 with a study Akeso leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3

The 5 of 6 with the most live studies.

Program
ivonescimabPhase 3 · 30 live · Carcinoma, Non-Small-Cell Lung · primary completion Dec 2026☆ Track
cadonilimabAK104Phase 3 · 19 live · Carcinoma, Hepatocellular · primary completion Nov 2026☆ Track
ligufalimabPhase 3 · 8 live · Neoplasms · primary completion Dec 2026☆ Track
AK120Phase 3 · 2 live · Dermatitis, Atopic☆ Track
ebronucimabPhase 3 · 1 live · Hyperlipidemias☆ Track

1 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Akeso’s own registered studies; Akeso’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

One of Akeso’s programs has a dated deal behind it: 1 licensed out. Each from the companies’ own releases and filings, linked; the registry does not record them.

Licensed out 1

What it is testing

The drugs Akeso’s studies test, most open studies first — 23 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 13 more

Coming up

29 of Akeso’s studies under way reach primary completion within a year, 8 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 2N’26
  2. 7D
  3. 2J’27
  4. 1F
  5. M
  6. 2A
  7. 5M
  8. 1J
  9. 1J
  10. 3A
  11. 1S
  12. 1O
  13. 3N

The 12 nearest

Show 7 more

Add all 29 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 18, 2026.

All 166 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now6740%Recruiting 41 · Not yet recruiting 26
  • Under way, not recruiting2012%
  • Completed6841%
  • Stopped early95%
  • Status unknown or other21%

Phase

  • Phase 289
  • Phase 177
  • Phase 335
  • Early Phase 11

Where

  • China146
  • Australia14
  • United States6
  • New Zealand5
  • Poland1
  • Canada1

Over the years

  1. 17
  2. 18
  3. 19
  4. 20
  5. 21
  6. 22
  7. 23
  8. 24
  9. 2825
  10. 1926

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Akeso.

  • Akeso
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    157 studies
  • Akesobio Australia Pty Ltd
    Regional office
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    9 studies →

Studies

Recruiting first, then most recently updated. Showing 50 of 166. Browse all 166 →